Celldex Therapeutics
CompanyUnited StatesFounded 1983
Celldex Therapeutics develops 2 assets, the furthest in phase 3 (barzolvolimab in chronic spontaneous urticaria). Mostly antibody acting on KIT and TSLP; based in the United States, founded in 1983.
- 2
- Assets
- Furthest stage
- Phase 3
- Raised
- $64.5M
- 13
- Trials
- 3
- Signals
Pipeline
2Blocks KIT signaling, depleting mast cells and suppressing mast-cell-mediated inflammation.
Phase 3, Antibody, KIT, chronic spontaneous urticaria, atopic dermatitis (Phase 2)
Neutralizes TSLP and stem cell factor, depleting mast cells and inhibiting Type 2 inflammatory responses.
Phase 1, Antibody, TSLP, mild-to-moderate asthma
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials21
- Funding rounds and grants2
- Deals5
- People23
- Signals7
- Similar companies6